History of Walgreens Boots Alliance

A pharmacy chain born of two different remedies

Walgreens Boots Alliance history grew out of two very different beginnings: a single drugstore opened by Charles R. Walgreen in a Chicago neighborhood in 1901, and a herbalist store founded by John Boot in Nottingham, England, in 1849. Each started as a local response to everyday needs—convenient, affordable medicines and remedies—but over the twentieth century both organizations reinvented retail pharmacy for mass markets. Their union in the 2010s stitched together American retail pharmacy, British-brand beauty and a European wholesale-distribution network into a global pharmaceutical and health-services conglomerate.

See TFE coverage of retail pharmacy, VillageMD and the COVID-19 vaccination rollout for related reporting.

Origins and founding: John Boot and Charles Walgreen

John Boot started a herbal remedy shop in Nottingham in 1849. His son, Jesse Boot, transformed that single shop into a national chain by the late nineteenth and early twentieth centuries, using mass distribution, vertical integration and a wide assortment of proprietary medicines. Boots became synonymous in Britain with pharmacy and with customer-facing brands—cosmetics, health aids and the No7 beauty line would later become recognizable product assets.

Charles R. Walgreen purchased the Chicago drugstore where he worked, at the corner of Bowen and Cottage Grove Avenues, in 1901. He built the business on convenience, extended hours and a focus on prescription service—shifting pharmacy from a back-room dispensary to a front-line retail offering. Walgreen experimented with new formats early: ice cream counters and in-store laboratories that could compound medicines. Those moves helped the brand spread across Chicago and eventually beyond.

Early development: scaling retail pharmacy in two markets

Walgreens and Boots followed different growth paths shaped by their home markets. In the United States, Walgreens focused on nationwide retail expansion and on converting foot traffic into prescription volume. The company emphasized store density in urban and suburban neighborhoods, the efficiency of centralized warehousing, and front-of-store merchandising that encouraged small, frequent purchases. These choices made Walgreens a go-to location for prescriptions and impulse items alike.

Boots grew through brand-building and integration with suppliers. By the twentieth century Boots had diversified into cosmetics, skincare and its own private-label products. Boots also developed a wholesale and distribution arm to feed its own stores and other retailers across the UK and continental Europe—an asset that would later prove attractive to buyers seeking logistics scale.

Consolidation in Europe: the rise of Alliance Boots

Alliance Boots was formed on July 31, 2006, when Boots Group PLC acquired Alliance UniChem Plc through a scheme of arrangement and changed its name to Alliance Boots plc. The combination brought together Boots’ pharmacy-led retail and consumer brands with Alliance UniChem’s pharmaceutical wholesale and distribution operations. On June 26, 2007, Alliance Boots was acquired by AB Acquisitions Limited, a vehicle controlled by funds advised by Kohlberg Kravis Roberts and by Stefano Pessina, and was taken private. Pessina became executive chairman in July 2007, placing him at the center of the group’s ownership, management and subsequent international expansion.

From strategic partnership to single global company

The decisive turning point between the two legacies came in the 2010s. On August 2, 2012, Walgreens acquired a 45% equity interest in Alliance Boots for $4.025 billion in cash and approximately 83.4 million Walgreens shares. The transaction also gave Walgreens an option to acquire the remaining 55%. The investment established joint purchasing and opened the possibility of deeper integration—recognizing that scale in purchasing, logistics and private-label brands could compress costs across geographies.

Walgreens exercised its option on August 5, 2014. On December 31, 2014, following a holding-company reorganization, Walgreens Boots Alliance became the publicly traded parent of Walgreens and acquired the remaining 55% of Alliance Boots for £3.133 billion in cash and 144.3 million Walgreens Boots Alliance shares. The new Delaware corporation maintained its principal executive offices in Deerfield, Illinois, and combined Walgreens’ dense U.S. store network with Boots’ branded consumer portfolio and Alliance Boots’ wholesale distribution business.

What the merger changed: a new business architecture

The alliance created a diversified revenue mix spanning U.S. retail pharmacy, UK and European retail and branded products, and pharmaceutical wholesale and distribution. In practice, integrating cross-border systems, harmonizing procurement and extracting cost synergies proved operationally complex. The merger also shifted the company’s strategic priorities—Walgreens was no longer solely an American retailer but a global health-care distributor and brand owner.

Leadership and organizational shifts

Two leadership strands remain central to the story. The first is the founding entrepreneurs—Charles Walgreen and the Boots family—whose early decisions set the cultural tone of convenience retail and branded customer offerings. The second is Stefano Pessina, a major shareholder who served as executive chairman of Alliance Boots from July 2007 through December 2014. After the combination, he served as Walgreens Boots Alliance’s acting chief executive and then chief executive, as well as executive vice chairman, before becoming executive chairman in March 2021. His senior roles placed him at the center of the combined company’s strategy and mergers and acquisitions, while operational executives managed its principal businesses.

Leadership transitions after the merger occasionally signaled strategic shifts: the company moved toward more explicit health-care services and away from a pure retail-first orientation. These choices influenced capital allocation, partnerships and the reconfiguration of store footprints.

Acquisitions, divestitures and ownership changes

The company’s most consequential ownership change was the two-stage path from alliance to full combination: a 45% stake in Alliance Boots followed by the acquisition of the remaining 55% and the creation of Walgreens Boots Alliance. That transaction consolidated ownership and created the public parent company under which the businesses initially operated.

Beyond that merger, WBA’s growth strategy included partnerships and investments that used its store network as a platform. The company expanded its health-care capabilities through joint ventures and both minority and controlling investments—an approach that reflected the limits of acquiring scale through pure retail roll-ups in markets where competitors and regulators were already entrenched.

Challenges, controversies and industry pressures

Like other major pharmacy chains, Walgreens Boots Alliance has faced sustained pressures and occasional controversies that tested its strategy and operations.

Competition and margin pressure: the retail pharmacy business sits between low-margin consumer goods and tightly regulated pharmacy services. Competition from discount chains, big-box retailers and online players compressed margins. Amazon’s entry into pharmacy services in 2020 added a new form of pressure: a digital-first competitor that could undercut price and convenience for prescription fulfilment.

Litigation over opioid dispensing: Walgreens was among the national pharmacy chains sued by states, local governments, tribes and private plaintiffs over the dispensing of prescription opioids. A multistate settlement agreement became effective on August 7, 2023; WBA reported that it had resolved claims with all states, territories and tribes and 99.7% of litigating subdivisions in settling states, while litigation not covered by the agreement remained. In April 2025, Walgreens separately agreed to pay the federal government $300 million, with an additional $50 million contingent on a sale, merger or transfer before fiscal 2032, to resolve Controlled Substances Act and False Claims Act allegations. The settlements did not constitute admissions or judicial determinations of liability.

Operational integration issues: merging large, distinct operating systems—U.S. retail, U.K. retail and European wholesale—created practical difficulties. IT integration, supply-chain harmonization and divergent market regulations slowed some initiatives and raised transition costs.

Pivoting toward health care: VillageMD and service expansion

One of the clearest strategic pivots after the merger was the attempt to convert pharmacy locations into hubs for broader primary-care services. Walgreens Boots Alliance pursued partnerships and investments in primary-care providers to place clinicians in or adjacent to stores—a bet that primary care, more than product sales, would deliver sustainable margin and deepen customer relationships.

On July 8, 2020, WBA announced plans to invest $1 billion in equity and convertible debt in VillageMD over three years, including an initial $250 million equity investment. The companies planned to open 500 to 700 Village Medical at Walgreens clinics in more than 30 U.S. markets over five years, and WBA expected to own approximately 30% of VillageMD after conversion of the debt. In 2021, WBA announced an additional $5.2 billion investment that increased its stake to approximately 63% and expanded the clinic target. The strategy later changed materially: VillageMD closed numerous clinics, and following Sycamore Partners’ acquisition of WBA on August 28, 2025, Walgreens and VillageMD began operating as separate standalone companies.

The approach was practical: use Walgreens’ real estate and local presence to offer routine medical care, chronic-disease management and preventive services, thereby increasing foot traffic and prescription adherence.

That pivot reflected a broader industry recognition: with pharmacy margins squeezed, integrated care and services offered a path to stable, higher-value revenue tied to population health management rather than just retail transactions.

COVID-19: testing, vaccinations and operational stress

The COVID-19 pandemic put Walgreens Boots Alliance squarely at the intersection of public-health duty and retail operations. Beginning in 2020 and continuing into 2021, Walgreens deployed its stores as testing sites, administered vaccines and reoriented store logistics to support temperature-controlled storage and mass inoculation.

Those efforts expanded the company’s public-health role and showcased the value of a dense retail footprint for delivering community health services. At the same time, the pandemic disrupted supply chains, changed consumer shopping patterns and accelerated digital adoption—pressures that forced the company to speed investments in online prescription management, curbside pickup and telehealth partnerships.

Recent developments and the company’s present form

In the most recent phase, Walgreens Boots Alliance has presented itself as a hybrid: a mass retail pharmacy chain, a Europe-focused retail and beauty brand owner, and a wholesale distributor with international reach. The firm’s modern revenue model combines:

• prescription-dispensing revenue and pharmacy services in the United States;
• retail sales and branded product margins in the United Kingdom and selected European markets;
• wholesale distribution contracts through Alliance Healthcare that supply independent pharmacies, hospitals and clinical services;
• health-care services revenue from clinic and care-delivery investments, including VillageMD during the period in which it was consolidated before the 2025 separation.

Because these streams operate under different regulatory and margin conditions, WBA’s management has had to balance short-term retail efficiency with long-term investments in services and logistics. The company has trimmed underperforming stores in oversaturated markets while attempting to increase the medical intensity of remaining locations. Digital prescription refills, in-store clinic rollouts and targeted private-label development from Boots’ brand portfolio have been central tactics.

Externally, the company continues to face competition from discount retailers, specialty pharmacy operators and e-commerce entrants. Internally, integrating cross-border operations, responding to litigation and adapting to shifting consumer behaviors remain ongoing management challenges.

Legacy and significance: how WBA changed pharmacy

Walgreens Boots Alliance matters because it crystallizes several enduring shifts in pharmacy and retail over the last century:

• Pharmacies became health hubs. Both Walgreens and Boots pushed pharmacy from a back-room function into a front-line health and wellness destination. WBA’s investments in clinics and primary care are a continuation of that trajectory.
• Scale became logistical power. Boots’ wholesale operations and Walgreens’ U.S. density demonstrate that distribution and purchasing scale are decisive levers in a low-margin sector.
• Brands can travel across borders. Boots’ consumer lines—most notably No7 and other private-label beauty products—became assets that a global operator could attempt to sell beyond their original markets, creating higher-margin opportunities than generic over-the-counter goods.
• The retail pharmacy became a platform. WBA’s strategic shift toward embedding primary care and services in stores shows how pharmacy footprints can be repurposed into community health platforms rather than simply points of sale.

Not every experiment has worked smoothly. Merging divergent operating systems and cultures across the Atlantic proved difficult; regulatory scrutiny and litigation forced costly compliance changes; and competition from digitally native players redefined customer expectations. But the company’s influence—on pharmacy practice, on branded health products, and on the idea of retail as a delivery channel for medical services—has been durable.

Conclusion: from corner drugstore to global health platform

The arc of Walgreens Boots Alliance runs from a corner drugstore in Chicago and a small Nottingham apothecary to a corporate structure that combines U.S. retail power, British brand heritage and European distribution muscle. The defining turning points were not just increases in store count but the strategic moves to combine brands with distribution and then to repurpose retail footprints for health care. The 2012 strategic stake in Alliance Boots and the full combination that followed in 2014 created the legal and operational framework for that transformation. Since then, the company has navigated litigation, digital disruption and a public-health crisis that both tested and proved the value of a dense, service-capable retail network.

Today, Walgreens Boots Alliance stands as a practical answer to a modern problem: how to make health care more convenient without surrendering margin to commodity retailing. Its future will depend on whether it can continue to translate store density into meaningful health services, keep distribution efficient across continents, and defend its brands against both online challengers and low-cost rivals—while meeting the regulatory and legal tests that come with being one of the world’s largest pharmacy operators.